rcca-header
Clinical Trials

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Type of Cancer
Solid Tumor
Site
Hackensack
Sponsor
Sarah Cannon
Protocol Number
Trillium-TTI-621-01
Phase of Trial
Phase I
To Learn More Call
(201)-510-0950